Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis	apoptosis	Drug	Cisplatin
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	cervical cancer
ICD-0-3	C53
Methods	qPCR, Western blot, Luciferase reporter assay, in vitro knockdown
Sample	cervical cancer tissues, cell lines (CaSki and HeLa)
Expression Pattern	up-regulated
Function Description	qRT-PCR indicated that HOXD-AS1 was overexpressed in CC tissues and cisplatin-resistant CC cells. Loss-of-function assays showed that downregulation of HOXD-AS1 expression suppressed chemoresistance of cisplatin-resistant CC cells. HOXD-AS1 targeted miR-130a-3p, and in gain-of-function assays miR-130a-3p could reverse cisplatin resistance of CC cells. miR-130a-3p in turn targeted zinc finger E-box homeobox 1 (ZEB1). These results collectively show that HOXD-AS1 can act as a competing endogenous RNA to upregulate ZEB1 expression via miR-130a-3p. Fruits of colony formation assays displayed that proliferation was inhibited in HOXD-AS1 down-regulated cells (CaSki-DDP and HeLa-DDP), and we could observe that cells with higher concentrations of cisplatin have weaker proliferation ability. Knock down of HOXD-AS1 led to enhanced apoptosis in CaSki-DDP and HeLa-DDP cells in contrast with the NC group when exposed to cisplatin and such effect was greater with increasing concentration of cisplatin.
Pubmed ID	29896986
Year	2018
Title	HOXD-AS1 Exerts Oncogenic Functions and Promotes Chemoresistance in Cisplatin-Resistant Cervical Cancer Cells

External Links